



# Financial Tear Sheet

## Corporate Profile

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

## Stock Information

### MYOK (Common Stock)

|             |                       |
|-------------|-----------------------|
| Exchange    | NASDAQ GS (US Dollar) |
| Price       | <b>\$56.45</b>        |
| Change (%)  | ▲ 0.70 (1.26%)        |
| Volume      | 85,276                |
| 52 Week Low | \$13.10               |
| Market Cap  | \$2,005,107,901       |
| Rolling EPS | -1.54                 |
| PE Ratio    | 0                     |

Shares Outstanding 35,966,061

Data as of 07/18/18 1:09 p.m. ET



## Recent Press Releases

### 06/26/18

MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

### 05/22/18

MyoKardia Announces Pricing of Public Offering of Common Stock

05/21/18

MyoKardia Announces Proposed Public Offering of Common Stock













## Upcoming Events

There are currently no events scheduled.

## SEC Filings

<< First | Previous | Next | Last >>

| Filing Date | Form   | Description  | Filing Group    | Downloads   |
|-------------|--------|--|-----------------|---|
| 07/13/18    | SC 13G | A statement of beneficial ownership of common stock by certain persons | Other           |             |
| 07/06/18    | 4      | Statement of changes in beneficial ownership of securities             | 3,4,5           |         |
| 06/29/18    | 4      | Statement of changes in beneficial ownership of securities             | 3,4,5           |     |
| 06/29/18    | 4      | Statement of changes in beneficial ownership of securities             | 3,4,5           |     |
| 06/15/18    | 8-K    | Report of unscheduled material events or corporate event               | Current Reports |     |
| 06/14/18    | 4      | Statement of changes in beneficial ownership of securities             | 3,4,5           |     |
| 06/14/18    | 4      | Statement of changes in beneficial ownership of securities             | 3,4,5           |     |

|          |   |  |       |   |   |   |   |
|----------|---|--|-------|---|---|---|---|
| 06/14/18 | 4 | Statement of changes in beneficial ownership of securities | 3,4,5 |  |  |  |  |
| 06/14/18 | 4 | Statement of changes in beneficial ownership of securities | 3,4,5 |  |  |  |  |
| 06/14/18 | 4 | Statement of changes in beneficial ownership of securities | 3,4,5 |  |  |  |  |

<< First | Previous | Next | Last >>

## Corporate Governance

Tassos Gianakakos      Chief Executive Officer

Jonathan Fox, M.D., Ph.D. Chief Medical Officer

Jake Bauer                      Vice President, Business Development and Business Operations

Ingrid Boyes                      Senior Vice President, Human Resources

Steven Chan                      Vice President, Corporate Controller

Joseph Lambing, Ph.D. Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell                      Senior Vice President of Drug Discovery

Iris Roth, Ph.D.                      Vice President, Program Team Leader